Back to mobile site

Oppenheimer Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)

August 26, 2025 6:35 AM EDT Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $98.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login